UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model by Palace J et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, Duddy M, Dobson 
C. UK multiple sclerosis risk-sharing scheme: a new natural history dataset 
and an improved Markov model. BMJ Open 2014, 4(1), e004073. 
 
 
Copyright: 
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non 
Commercial (CC BY-NC 3.0) l icense, which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/3.0/ 
DOI link to article: 
http://dx.doi.org/10.1136/bmjopen-2013-004073  
Date deposited:   
25/09/2015 
  
UK multiple sclerosis risk-sharing
scheme: a new natural history dataset
and an improved Markov model
Jacqueline Palace,1 Thomas Bregenzer,2 Helen Tremlett,3 Joel Oger,4 Fheng Zhu,3
Mike Boggild,5 Martin Duddy,6 Charles Dobson7
To cite: Palace J,
Bregenzer T, Tremlett H, et al.
UK multiple sclerosis risk-
sharing scheme: a new
natural history dataset and an
improved Markov model.
BMJ Open 2014;4:e004073.
doi:10.1136/bmjopen-2013-
004073
▸ Prepublication history and
additional material for this
paper is available online. To
view these files please visit
the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-004073).
Received 19 September 2013
Revised 10 December 2013
Accepted 12 December 2013
For numbered affiliations see
end of article.
Correspondence to
Dr Jacqueline Palace;
jacqueline.palace@ndcn.ox.
ac.uk
ABSTRACT
Objectives: In 2002, the UK’s National Institute for
Health and Care Excellence concluded that the multiple
sclerosis (MS) disease modifying therapies; interferon-
β and glatiramer acetate, were not cost effective over
the short term but recognised that reducing disability
over the longer term might dramatically improve the
cost effectiveness. The UK Risk-sharing Scheme (RSS)
was established to ensure cost-effective provision by
prospectively collecting disability-related data from UK-
treated patients with MS and comparing findings to a
natural history (untreated) cohort. However,
deficiencies were found in the originally selected
untreated cohort and the resulting analytical approach.
This study aims to identify a more suitable natural
history cohort and to develop a robust analytical
approach using the new cohort.
Design: The Scientific Advisory Group, recommended
the British Columbia Multiple Sclerosis (BCMS)
database, Canada, as providing a more suitable natural
history comparator cohort. Transition probabilities were
derived and different Markov models (discrete and
continuous) with and without baseline covariates were
applied.
Setting: MS clinics in Canada and the UK.
Participants: From the BCMS database, 898
‘untreated’ patients with MS considered eligible for
drug treatment based on the UK’s Association of
British Neurologists criteria.
Outcome measure: The predicted Expanded
Disability Status Scale (EDSS) score was collected and
assessed for goodness of fit when compared with
actual outcome.
Results: The BCMS untreated cohort contributed
7335 EDSS scores over a median 6.4 years (6357
EDSS ‘transitions’ recorded at consecutive visits)
during the period 1980–1995. A continuous Markov
model with ‘onset age’ as a binary covariate was
deemed the most suitable model for future RSS
analysis.
Conclusions: A new untreated MS cohort from British
Columbia has been selected and will be modelled
using a continuous Markov model with onset age as a
baseline covariate. This approach will now be applied
to the treated UK RSS MS cohort for future price
adjustment calculations.
INTRODUCTION
In January 2002, the UK’s National Institute
of Health and Care Excellence (NICE)
opted not to recommend the use of the
disease modifying therapies (DMTs) inter-
feron β and glatiramer acetate for multiple
sclerosis (MS) on the basis of cost-
effectiveness analyses using data derived
from the pivotal 2–3-year randomised con-
trolled trials.1 However, they recognised that
uncertainties over the assumptions made in
the modelling could unpredictably influence
the long-term estimates of cost effectiveness.
Thus in February 2002, the UK’s Department
of Health launched the ‘Risk-sharing
Scheme’ (RSS)2 with a circular entitled the
‘Cost effective provision of DMTs for people
with MS’ in collaboration with the
Association of British Neurologists (ABN),
the MS Trust, the MS Society and the
pharmaceutical companies manufacturing
interferon β and glatiramer acetate. Between
Strengths and limitations of this study
▪ Identification of a new natural history cohort for
the UK Risk-sharing Scheme, consisting of
untreated patients with multiple sclerosis (MS) in
an era when disease-modifying drugs for MS
were not available, minimising potential selection
bias.
▪ Identification and validation of a Markov model
for disease progression in MS which can be
applied to data collected in clinical practice over
multiple years of follow-up.
▪ The identification of an analytical model which
can use data collected at any time point within
the follow-up period.
▪ The study related to observational data collected
in clinical practice; unseen or unmeasured con-
founding cannot be adjusted for.
▪ Different techniques to assess effectiveness of
drugs in observational studies such as matching
on propensity scores cannot be directly com-
pared to this methodology.
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2002 and 2005 the scheme enrolled over 5000 patients
with MS initiating a DMT in the UK, with the aim of
measuring their disability annually over a 10-year period.
The principle of the RSS is to use a Markov model to
predict, for each DMT separately, the expected move-
ment of patients between the Expanded Disability Status
Scale (EDSS) states both ‘on’ and ‘off’ treatment. For
patients ‘off’ treatment, the model uses a matrix of tran-
sition probabilities derived from the actual progressions
seen in the ‘natural history’ comparator cohort. These
transition matrices are modified for patients ‘on’ treat-
ment by multiplying by the HR (relative rate of disease
progression) derived separately for each DMT from the
pivotal randomised controlled clinical trials. The model
then predicts how the distribution of patients will evolve
over a 20-year horizon, starting with the actual distribu-
tion at baseline for the primary analysis RSS cohort.
Comparing the average observed loss of utility (average
utility-weighted disease progression) for patients in the
RSS to the expected loss calculated by the Markov
model for patients ‘on’ treatment; it is calculated as
follows. The expected ‘benefit’ of treatment (with a spe-
cific DMT) is the ‘hypothetical’ difference between the
expected outcome without treatment and with treat-
ment, as calculated in each case from the Markov
model. The actual ‘benefit’ of treatment is the ‘observed’
difference between the expected outcome without treat-
ment and the actual outcome with treatment. The ‘devi-
ation’ of the actual benefit from the expected is the
primary outcome measure and calculated as a percent-
age of the expected benefit. This measure can have
negative or positive values so that a negative deviation
implies that the observed benefit was greater than pre-
dicted, a positive deviation suggesting that it was worse
than predicted and a value of 0 indicating that it was
exactly as predicted. A positive deviation beyond the
level agreed (confidential and individual between each
pharmaceutical company and the Department of
Health) would lead to a price adjustment down to
achieve the target cost effectiveness. Details can be
found in the Health Service Circular.2
The original cost-effectiveness model3 produced a
target outcome based on transition probabilities
obtained from a pre-existing natural history (DMT
naive) cohort of patients from London, Ontario,
Canada along with HRs from the pivotal randomised
control trials (unpublished data provided to the
Department of Health by the manufacturers).
Complementary quality of life data collected by the MS
Trust4 and cost data from Kobelt et al5 were used to
populate the cost-effectiveness model. The targets
ensured that the UK’s National Health Service (NHS)
benchmark of £36 000 (€46 000/US$56 000) per
quality-adjusted life year (QALY) was reached over a
20-year projection, based on a planned 10-year follow-up
period within the RSS with two yearly interim analyses.
Before being allowed to enter the scheme, the cost of
each drug was assessed against the NICE bench mark
over a 20-year time horizon. Price reductions were
implemented to ensure each product reached the target
cost per QALY using the original NICE calculations,3 an
average 13.7% price reduction was achieved for the NHS
at the outset of the Scheme.
The 2-year analysis revealed significant inconsistencies
in a number of sensitivity analyses.6 Depending on the
underlying assumptions, some analyses suggested that
observed disability progression in the treated cohort was
worse than that predicted for the historical untreated
cohort while others demonstrated the contrary effect. A
detrimental effect of DMT did not match the described
effect on short term, 2–3 year, disability seen in the ran-
domised placebo controlled trials.7–12 With the predeter-
mined analytical approach (based on a discrete Markov
model) appearing to produce unreliable results with
wide variation, a decision was made to postpone any
decision on cost-effectiveness to allow for a reappraisal
of the process and to reconsider whether the statistical
models and control data chosen were ‘fit for purpose’.
In retrospect, both the control dataset and analysis
model selected, when setting up the RSS, were found to
have intrinsic flaws that made them unsuitable for the
task.6 The natural history cohort (from London,
Ontario, Canada) was unexpectedly found to contain
retrospectively smoothed disability data (rather than
actual, real-time collected disability scores), censoring
any improvement in EDSS. Comparing our uncensored
treated cohort to data retrospectively smoothed in this
way would have the effect of unpredictably underestimat-
ing any treatment effect. In addition, individual-level
patient data were not available from the London,
Ontario cohort, which prevented precise baseline match-
ing between the two cohorts, limiting our validation of
the underlying (Markov) model for disease progression.
Furthermore, there were only 342 patients matching the
ABN prescribing criteria from which to generate the
models.
This paper outlines the development of a more appro-
priate analysis plan and the choice of a cohort fit for the
needs of the scheme. The method described will be
applied in the 4-year and 6-year cost-effectiveness ana-
lyses. The analysis plan was approved by the scheme’s
independent Scientific Advisory Group in December
2012 in advance of unlocking the newly collected 4-year
and 6-year UK RSS data planned for autumn 2013.
METHODS
Identification of a new MS natural history dataset
The Scientific Advisory Group undertook a detailed
examination of all the available dataset through litera-
ture reviews, expert opinion, discussion with the clinical
leads for the RSS and discussion with the Sylvia Lawry
Centre for Multiple Sclerosis Research, Germany
(http://www.slcmsr.net). Selection criteria included
availability of EDSS score measurements and access to
the unprocessed (actual) scores (ie, no data smoothing
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or other data manipulation). Other factors considered
were size of the database, prospective data collection
and length of follow-up, and the broader setting such as
a close match to the UK in terms of the health system
and MS prevalence in the underlying population. While
no single perfect dataset existed, the British Columbia
Multiple Sclerosis (BCMS) database, Canada (est. 1980)
was identified as the best natural history comparator
cohort for our purposes.13 14 In this dataset—as in the
RSS—actual EDSS scores were recorded prospectively. It
is estimated to capture 80% of the BCMS population15 16
and as such is considered representative of the wider MS
population. EDSS scores were recorded by MS specialist
neurologists after a face-to-face consultation with the
patient; this typically occurred at the annual MS clinic
visit. Patient data was not truncated if secondary-
progressive MS was reached; that is, all relapse-onset
patients with MS and their respective EDSS scores were
considered eligible. By 2004, the database had records
for over 5900 patients spanning 28 years (>25 000 cumu-
lative years) of prospective follow-up. Until 1996 DMTs
were not widely available in British Columbia.
Patient and data selection from the BCMS database
In order to generate relevant data for our needs,
patients were only selected from the BCMS database if
they fulfilled the 2001 ABN criteria for interferon β and
glatiramer acetate (IFN-β/GA) use (adapted from
online supplementary appendix IV Health Service
Circular 2002/2004), defined as: EDSS≤6.5; ≥18 years
old; two relapses in the last 2 calendar-years.
Baseline for each patient was the ’first eligibility date,’
meaning the first date at which a patient fulfilled the
ABN eligibility criteria. Only patients with definite MS
(Poser et al’s criteria17) and a minimum of two EDSS
scores at least 9 months apart were considered.
In order to be comparable with the RSS data the fol-
lowing adjustments and selection were applied:
1. EDSS scores taken during a relapse or when disability
was affected by other factors considered largely unre-
lated to MS (eg, hip fracture) were excluded.
2. For the original discrete Markov model (see below)
as well as visual presentation of the yearly descriptive
data (see Results section), annual EDSS scores were
needed. However, as is typical in clinical practice, not
all visits/EDSS assessments occurred at exactly yearly
intervals and the exclusion of some EDSS scores (eg,
due to a relapse or hip fracture) also affected the
availability of a yearly score. Therefore, data was
selected such that only EDSS scores 1 year apart (± 3
calendar months) were considered. See online sup-
plementary appendix 1 for further details.
3. For the continuous Markov model, (see below) all eli-
gible EDSS scores were used regardless of their meas-
urement interval, that is, no yearly data selection, as
in (2), was needed.
4. All patient data was truncated to the end of 1995 (ie,
the last full year in which the DMTs were not widely
available in BC although initially it was planned to
truncate individual patient profiles only once a DMT
was initiated (in order to maximise the number of
EDSS assessments), even when this extended past
1995 when treatment would have been available). It
became apparent that this introduced a bias into the
data, likely related to ‘indication bias,’ whereby
patients ‘doing well’ would be less likely to start a
DMT.
Analysis
The primary purpose of the analytical work was to find
the best statistical model able to predict EDSS progres-
sion in a natural history cohort based on entry demo-
graphic and clinical data. The following models were
applied in the current study and their performances
were critically evaluated:
A. The discrete Markov model18 as in the original 2-year
analysis,6 that is, disability scores (EDSS) had to be
measured at discrete, fixed time points.
B. A continuous Markov model allowing for EDSS
scores to be collected at any time, that is, at any
unevenly spaced time intervals, as is typical in clinical
practice.19 Such a model also allowed covariates to be
included. This model allows for a more complete use
of EDSS scores collected at irregular time intervals
both in the BCMS and RSS cohorts.
With regard to the ‘MS course’ (ie, relapsing remitting
vs secondary progressive) as a potential covariate, we did
not distinguish between these disease states when devel-
oping the Markov models because secondary progressive
MS is simply a later stage of the relapsing remitting form
of the disease and the transition has considerable
overlap.
Predicting outcomes in the continuous Markov model (b)
A multistate model algorithm (‘R’ library ‘msm’19)
allows the EDSS distribution to be predicted at any time
t (see online supplementary appendix 2 for further
details).
To keep computations feasible, only integer EDSS
values were used and fractional values rounded down
(ie, EDSS 1.5 was scored as 1, 2.5 was scored as 2 etc).
Moreover, ‘msm’ as a tool for multistate modelling requires
a consecutive numbering of (disease) states, starting
with ‘1’. Therefore the (rounded down) EDSS 0 became
‘state 1’, EDSS 1 ‘state 2’ etc, leading to the 10 EDSS
‘states’ (1–10) representing EDSS 0–9. Transition prob-
ability and intensity matrices as the output of these
models were then used to predict disease progression in
terms of EDSS as follows.
Covariates considered in the models
The selection of potential covariates by the scientific
advisory group was based on; (1) those which were reli-
ably and consistently recorded in both the BCMS and
the RSS database and (2) a priori knowledge of those
associated with the outcome of disability progression. As
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a result, sex, age at MS symptom onset, as well as disease
duration and disability (EDSS)—combined into a
Multiple Sclerosis Severity Score (MSSS)20 were tested in
the continuous Markov model with up to two covariates.
In addition, for the more promising models an alterna-
tive model was considered with dichotomous covariates
(split at the median) replacing the continuous variables.
This has the advantage that the resulting model can be
formulated as the aggregate of a small number of dis-
crete Markov models, so computations can be carried
out without requiring special software, especially since
the EDSS values in the RSS have been collected at strict
yearly intervals, as opposed to the BCMS data which was
based on routine clinical practice, and therefore do not
necessitate a continuous model.
Critical evaluation of the models was performed using
the following validation techniques, with the goal being
to identify the most appropriate model to represent the
natural progression of MS (see online supplementary
appendix 3 for further details).
1. Transition probabilities derived from the complete
eligible, BCMS natural history data were applied to
the baseline data to predict outcomes over the subse-
quent 10 years to assess how well it matched the
observed data from which the model was derived.
2. The BCMS dataset was repeatedly randomly divided
into two subsets of equal size, with one-half only
being used to derive transition probabilities (as in
#1). The probabilities derived from this half were
then applied to the baseline characteristics of the
second half, generating a model whose goodness of
fit could be judged against the actual, observed
10-year disability data of this second half.
Measuring goodness of fit
Goodness of fit was assessed via visual inspection of the
graphical displays as well as numerically. These included
progression over time (mean EDSS profiles) for the
cohort as a whole as well as comparisons with the pro-
portions in a particular EDSS state over time.
For the numerical assessment a classical mean square
prediction error (weighted root mean square over years
of the prediction error in the average quantity shown,
weighted by the number of patients contributing data in
the given year) and the likelihood, resulting from the
maximum likelihood algorithm were calculated for each
of the covariate models to allow comparison.
RESULTS
Data description
The baseline demographics showed the BCMS and RSS
cohorts to be remarkably well matched. Patient
characteristics are shown in table 1.
The natural history BCMS comparator dataset com-
prised of 898 patient profiles with 7335 EDSS scores pro-
viding 6357 transitions between consecutive EDSS states,
that is, 6357 ‘events’ where EDSS values were recorded
at consecutive visits. In any given ‘transition’, a patient’s
EDSS could increase, decrease or stay the same.
Table 1 Characteristics of patients reaching the ABN criteria in the BCMS database after 1980 (the ‘natural history’
untreated comparator cohort) and the RSS cohort
Baseline (eligible for DMT) BCMS (1980–1995*)
RSS full cohort
RSS analysis cohort†
N 898 5610
4138
Females: n (%) 666 (74.2) 4162 (74.2)
3125 (75.5)
Age at baseline, years: mean (SD; range) 37.2 (9.32; 18–69) 39.4 (9.05; 15–73)
38.4 (8.58; 18–73)
Age at onset of MS, years: mean (SD; range) 29.3 (8.65; 3–61) 30.5 (8.52; 5–68)
30.5 (8.38; 5–68)
Disease duration at baseline, years: mean (SD; range) 7.9 (6.89; 0.2–38.9) 8.8 (7.47; 0–46)
7.7 (6.62; 0–41)
SPMS documented at baseline‡ n (%) 141 (15.7) 772 (13.8)
–
Relapses in the past 2 years prior to eligibility: median (quartiles) 2 (2–3) 3 (2–3)
3 (2–3)
First eligible EDSS: median (quartiles; range) 2 (1, 3.5; 0–6.5) 3.5 (2.0, 5.0; 0–8.0)
3.0 (2.0, 4.0; 0–6.5)
‘Eligibility’ refers to the first time a patient fulfilled the ABN criteria.
*Data were truncated to 1995 in the final models to minimise DMT exposure in the cohort.
†‘Analysis cohort’ is the subset of patients eligible for the analysis (eg, treated patients, at least one postbaseline EDSS available, etc).
‡All were still DMT eligible.
ABN, Association of British Neurologists; BCMS, British Columbia Multiple Sclerosis database; DMT, disease modifying treatment; EDSS,
Expanded Disability Status Score; RSS, Risk-sharing Scheme.
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Discrete Markov model
When applying the discrete Markov model to the BCMS
reference data, the goodness of fit was unsatisfactory,
underestimating EDSS in earlier years and overestimat-
ing in later years (see figure 1). Consequently, the dis-
crete Markov model was no longer considered
appropriate, and the development of a continuous
Markov model was pursued.
Continuous Markov models
The following continuous 10-state Markov models (EDSS
0–9), with and without covariates, were evaluated:
1. Model without covariates
2. One covariate model with age at onseti
3. One covariate model with MSSSi at baseline
4. One covariate model with disease durationi at
baseline
5. One covariate model with sex
6. Two covariate model: sex and age at onseti
7. Two covariate model: MSSSi at baseline and age at
onseti
8. Two covariate model: disease durationi at baseline
and age at onseti
There was a systematic deviation with a slight overesti-
mation when the continuous Markov model without cov-
ariates was applied (figure 2). Hence this model was not
considered further.
After validation was repeated for all covariate models
(table 2), it was noted that inclusion of a second covari-
ate did not reveal any additional benefits. With one cov-
ariate, the model with ‘age at onset’ as a binary
covariate (median: 28 years) was selected because it dis-
played the smallest −2 log likelihood and minimal EDSS
prediction error (see table 2). Further, the goodness of
fit was acceptable when comparing the predicted and
observed EDSS profiles, as shown in figure 3A. A more
detailed comparison of observed and expected propor-
tions ‘per EDSS state’ is shown in figure 3B which con-
firmed that no systematic deviations were present which
might otherwise have been cancelled out when only
looking at an average EDSS profile. It was concluded
that only random fluctuation remained, and a systematic
deviation was no longer visible. When comparing figure
1 with figures 2 or 3 it should be noted that the former
is based on the annual EDSS data which were obtained
as described in online supplementary appendix 1 while
figures 2 and 3 show the EDSS at any time t, that is, not
necessarily when an observation was recorded (while the
continuous Markov model takes into account all observa-
tions at any time t it is not straightforward to define
what the ‘observed EDSS’ at any time t is in a graphic
representation; for details on how to define and calcu-
late what is the observed EDSS at a given time see
online supplementary appendix 2).
Using this ‘best’ model, transition probabilities were
extracted from half of the BCMS cohort and applied to
the other half. This gave good predictions, with the
mean EDSS profiles (observed vs predicted) being
similar to each other and to those of the entire cohort.
In summary, the continuous Markov model with a
single covariate—onset age—was considered the model
of choice to be used in future RSS analysis. The respect-
ive transition matrices are presented in table 3.
DISCUSSION
This paper outlines the successful identification of a
more suitable natural history cohort for the UK MS RSS,
with the British Columbia, Canada dataset now replacing
the London, Ontario, Canada cohort in the RSS analysis
plan. The analytical work is based on a Markov model
which has been frequently used for ordinal data from
relapsing (remitting) diseases, especially MS.21–23
Figure 1 Transition probabilities obtained from the BCC
dataset using the discrete Markov model were then applied to
the baseline Expanded Disability Status Scale (EDSS) of the
same cohort, projected over 10 years to produce a predicted
mean EDSS outcome (red) and compared with the observed
mean EDSS course of the cohort (blue).
Figure 2 Transition probabilities obtained from the BCC
dataset using the continuous Markov model were then applied
to the baseline Expanded Disability Status Scale (EDSS) of
the same cohort, projected over 10 years to produce a
predicted mean EDSS outcome (red) and compared with the
observed mean EDSS course of the cohort (blue).
iTwo variants were implemented: continuous (original) data and a
‘binary’ version with the median used for categorisation.
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Further, because use of the British Columbian data
has now allowed access to a richer dataset, including full
access to original, ‘real-time’ disability (EDSS) assess-
ments, as well as individual patient level, we have been
able to explore and develop more appropriate
approaches. Specifically, we were able to employ more
advanced statistical models, making use of all the avail-
able data and including clinically relevant patient-level
characteristics as covariates in order to identify the most
accurate predictive model to be applied to the RSS.
Finally, we observed that to minimise ‘indication bias’ in
relation to initiation of a DMT in the natural history
cohort (British Columbia), censoring (data truncation)
was more appropriate at the population (rather than
individual) level.
Findings from our validation procedures indicate
future feasibility with respect to obtaining reliable cost-
effectiveness results in the upcoming 6-year RSS ana-
lyses. For instance, visualisation of the predicted and
observed outcomes in the final model showed an almost
perfect overlap, with a one-covariate model, with no add-
itional improvements from introducing further covari-
ates. In addition, the final model was able to predict
accurately the MS disease course (disability) in half of
the cohort (randomly selected) having obtained the
transition probabilities from the other half. These obser-
vations along with the baseline comparability of the
BCMS and the RSS cohorts suggest the transition prob-
abilities from the BCMS cohort within this model can be
used to predict the untreated progression of patients in
the RSS.
An additional strength of this continuous model is the
ability to include all valid disability (EDSS) assessments,
regardless of their exact timing, maximising data usage.
We acknowledge the potential limitations of using a his-
torical control from a geographically discrete popula-
tion. It is possible that the natural history of MS has
changed over time or that the BCMS population is not
representative of a UK one. However, in British
Columbia, it has been previously shown that disability
progression (as measured by the EDSS) has not substan-
tially changed overtime (1980–200924). Further, we have
previously shown that the use of a ‘contemporary’
untreated control cohort—that is, where patients are
potentially eligible for a DMT in an era when the DMTs
are readily available, but remain untreated—is subject to
indication bias and thus a historical control cohort, with
data collected pre-DMT use, is likely to be more appro-
priate.25 Although we are proposing using a dataset
from Canada (as was the original RSS natural history
dataset) and cannot rule out differences between the
BCMS patients and the UK RSS cohort, we are reassured
that the baseline features are comparable except base-
line EDSS, but in the underlying Markov model we cal-
culate the transition probabilities between EDSS ‘states’,
and different baseline EDSS distributions would only
matter if baseline EDSS as such had a prognostic value,
which does not seem to be the case when looking at the
Table 2 ‘Goodness of fit’ statistics for the 10-state† disability (EDSS) Markov models
Description of each 10-state† disability model
−2 Log likelihood‡ Prediction errors (years 1–10)§
×1000 Cells EDSS Utility
No covariates 17.152 2.20 0.24 0.022
One covariate models
Age at onset, binary 17.458 1.39 0.09 0.009
Age at onset, continuous 17.599 1.58 0.13 0.007
MSSS at baseline, binary 17.460 1.41 0.10 0.008
MSSS at baseline, continuous 17.457
Disease duration, binary 17.462 1.33 0.10 0.009
Disease duration, continuous 17.557
Sex 17.470 1.32 0.10 0.008
Two covariates models
Sex and age at onset, binary 17.603 1.51 0.14 0.007
Sex and age at onset, continuous 17.618
Age at onset and MSSS, binary 17.609 1.53 0.14 0.007
Age at onset and MSSS, continuous 17.618
Age at onset and disease duration, binary 17.603 1.52 0.14 0.007
Age at onset and disease duration, continuous 17.618
Primary goodness of fit statistic is −2 log likelihood; prediction errors have only been calculated for the binary versions of the individual
models except for the ‘final’ model with age at onset as covariate where prediction errors have been calculated for both versions.
†The 10 disability states refer to EDSS 0–9, that is, EDSS 0 is ‘state 1’, EDSS 1 is ‘state 2’, etc.
‡Log likelihood statistic as calculated by ‘msm’ module, see Jackson19 for details; lower values implying a better model (to be compared
within each class of models, eg, one-covariate and two-covariate models).
§Prediction errors, averaged over years 1–10, for (a) the EDSS distribution in individual cells, (b) average EDSS, (c) average utility (see
definitions in the online supplementary appendix 3, comparing the values predicted by the model with the ‘observed’ values using the method
of midpoint interpolation (see online supplementary appendix 2).
EDSS, Expanded Disability Status Score; MSSS, Multiple Sclerosis Status Score.
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rates of EDSS progression stratified by EDSS at baseline.
In addition, the underlying ethnicity of the two jurisdic-
tions was similar; around the time of the cohort selec-
tion in British Columbia, 30.2% of the population
self-identified as British and within the wider BCMS
database, >90% were Caucasian,26 27 which is compar-
able to the UK cohort. Both cohorts may have enrolled
a small number of patients with neuromyelitis optica (we
estimate this to be less than 0.5% of the total28) because
the availability of the antibody assay occurred after 2007
(and after enrolment to the RSS scheme). An additional
limitation is the potential for different ways of measuring
the EDSS scores between the BCMS and the UK RSS
cohorts because of changes in how the EDSS is inter-
preted over time and also because of differences in the
physicians performing the assessments.
Observational studies, such as the RSS, provide a prag-
matic approach when assessing drug effectiveness in a
disease such as MS. As MS disability accrues over
decades, the cost-effectiveness of disease modifying treat-
ments cannot be assessed by short-term randomised con-
trolled trials. However, observational studies are not
without their own unique challenges. Identifying and
validating models to predict the untreated outcome of
treated cohorts is a crucial step to measuring the long-
term benefits of MS treatments. MS is the commonest
cause of progressive disability in the western world, thus
identification of treatments that might significantly
impact long-term disability outcomes in MS could have
major cost and quality of life benefits. Additionally, any
models developed here would be readily transferable to
other chronic diseases.
The current model described here will form the basis
for calculating the drug cost per QALY and for inform-
ing decisions on price adjustment in order to deliver the
treatments cost effectively to UK patients with MS in an
ongoing manner. The model will be used to calculate
the HR at which each product delivers efficacy against
Figure 3 Transition probabilities
obtained from the BCC dataset
using the continuous Markov
model with one covariate ‘age at
onset’ (binary version) were then
applied to the baseline Expanded
Disability Status Scale (EDSS) of
the same cohort, projected over
10 years to produce a predicted
outcome (red) compared with the
observed course of the cohort
(blue): (A) mean EDSS shown in
the predicted and actual cohorts.
(B) The proportion of patients
predicted to be in each of the 10
EDSS states over time (state 1;
EDSS 0, state 2; EDSS 1 and
1.5, state 3; EDSS 2.0 and 2.5,
state 4; EDSS 3.0 and 3.5, state
5; EDSS 4.0 and 4.5, state 6;
EDSS 5.0 and 5.5, state 7; EDSS
6.0 and 6.5, state 8; EDSS 7.0
and 7.5, state 9; EDSS 8.0 and
8.5, state 10; EDSS 9.0 and 9.5).
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the NICE agreed cost per QALY and should any product
fall short price reductions will be implemented by the
DH.
Further work on repeated measures modelling, testing
the models on other untreated appropriate MS datasets
and identifying sensitivity analyses (such as the effect of
drop outs, switching to a different class of DMT and the
effects of treatments on backward transitions, ie, disabil-
ity improvements) are also planned.
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Correction
Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risksharing scheme:
a new natural history dataset and an improved Markov model. BMJ Open 2014;4:e004073. The
fifth author’s name was misspelt in this paper. The correct spelling of this author’s name is
Feng Zhu.
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